40
Participants
Start Date
June 5, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
January 31, 2039
NXC-201 CAR-T
NXC-201 (formerly HBI0101) CAR-T is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 CAR-T is provided fresh without cryopreservation.
RECRUITING
Memorial Sloan Kettering Comprehensive Cancer Center, New York
RECRUITING
Winship Cancer Institute, Emory University, Atlanta
RECRUITING
Cleveland Clinic, Cleveland
RECRUITING
University of Cincinnati Cancer Center, Cincinnati
RECRUITING
Barbara Ann Karmanos Cancer Institute, Detroit
RECRUITING
Masonic Cancer Center, University of Minnesota, Minneapolis
RECRUITING
Washington University Siteman Cancer Center, St Louis
RECRUITING
The University of Kansas Cancer Center, Fairway
RECRUITING
Huntsman Cancer Institute at the University of Utah, Salt Lake City
RECRUITING
University of California Los Angeles, Los Angeles
RECRUITING
City of Hope, Duarte
RECRUITING
Stanford University, Stanford
RECRUITING
Sutter Health Alta Bates, Berkeley
RECRUITING
University of California Davis Medical Center, Sacramento
RECRUITING
Swedish Cancer Institute, Seattle
RECRUITING
Baptist Memorial Hospital, Memphis
RECRUITING
Tufts Medical Center, Boston
RECRUITING
Boston University Medical Center, Boston
Lead Sponsor
Collaborators (1)
Immix Biopharma, Inc.
INDUSTRY
Nexcella Inc.
INDUSTRY